investment-in-health-systems

Access to healthcare at AstraZeneca goes beyond our medicines. We provide healthcare solutions along a continuum of care — from prevention, awareness, diagnosis and treatment, to post-treatment and wellness. We work across our main therapy areas to address unmet medical needs and health disparities.

Notes:

1. People 'reached' is defined per programme, depending on the operations: Healthy Heart Africa — includes the number of blood pressure screenings; Phakamisa - includes the number of women reached through early breast cancer detection and awareness; Healthy Lung Asia methodology updated from 2017 - 'people reached' includes only those diagnosed or educated or treated.

2. Phakamisa was placed on hold during 2020 due to contract expiry with NGO partner. The programme was relaunched in Nov 2020. Data expected from 2021.

3. 2019 Healthy Lung Asia data has been updated with data received post 2019 Data Summary publication.

4. With exception of healthcare workers trained, all other Healthy Lung Gulf activities were paused due to COVID-19.

5. All Healthy Lung Saudi Arabia activities were paused during 2020 due to COVID-19.

6. After limited activities in Q1 2020, Healthy Lung Egypt programme was paused due to the conversion of healthcare facilities to COVID-19 isolation units.

Notes:

1. 2019 Healthy Lung Asia data has been updated with data received post 2019 Data Summary publication.

2. All Healthy Lung Saudi Arabia activities were paused during 2020 due to COVID-19.

3. With exception of healthcare workers trained, all other Healthy Lung Gulf activities were paused due to COVID-19.

4. After limited activities in Q1 2020, Healthy Lung Egypt programme was paused due to the conversion of healthcare facilities to COVID-19 isolation units.

Notes:

1. Phakamisa was placed on hold during 2020 due to contract expiry with NGO partner. The programme was relaunched in Nov 2020. Data expected from 2021.

2. 2019 Healthy Lung Asia data has been updated with data received post 2019 Data Summary publication.

3. With exception of healthcare workers trained, all other Healthy Lung Gulf activities were paused due to COVID-19

4. All Healthy Lung Saudi Arabia activities were paused during 2020 due to COVID-19.

5. After limited activities in Q1 2020, Healthy Lung Egypt programme was paused due to the conversion of healthcare facilities to COVID-19 isolation units.

You are now leaving AstraZeneca.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Important notice for users

You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.

Analyst interactive reporting centre

Menu

Sustainability

Access to healthcare

Environmental protection

Ethics and transparency

Investment in health systems